SavedAdd your journal

Journals / Acta Medica Nicomedia / 2026 / Cilt: 9

COMPARATIVE EFFECTS OF RESVERATROL AND CAFFEIC ACID ON CELL VIABILITY, APOPTOSIS, AND PTEN/AKT1 SIGNALING IN MCF-7 BREAST CANCER CELLS

RESVERATROL VE KAFEİK ASİDİN MCF-7 MEME KANSERİ HÜCRELERİNDE HÜCRE CANLILIĞI, APOPTOZ VE PTEN/AKT1 SİNYALLEŞMESİ ÜZERİNDEKİ KARŞILAŞTIRMALI ETKİLERİ

Oya Korkmaz(MALATYA TURGUT ÖZAL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2923-5869
Pages
1–8
Publication Date
2026-08-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The biological effects of resveratrol appear to be associated with the regulation of mitochondrial apoptosis and the PTEN/AKT1 signaling axis, supporting its potential role as a complementary therapeutic candidate in ER-positive breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study evaluates the effects of resveratrol and caffeic acid on viability, proliferation, and apoptosis in ER⁺ MCF-7 breast cancer cells, with additional analysis of PTEN/AKT1-related transcriptional changes.
📊
Key Findings & Data:Methods: MCF-7 cells were exposed to resveratrol at concentrations ranging from 5 to 50 µM and to caffeic acid at concentrations of 10 to 50 µM for incubation periods of 24, 48, and 72 h.
💡
Conclusion & Impact:The biological effects of resveratrol appear to be associated with the regulation of mitochondrial apoptosis and the PTEN/AKT1 signaling axis, supporting its potential role as a complementary therapeutic candidate in ER-positive breast cancer.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Apoptoz · Resveratrol · Hücre Proliferasyonu

Abstract

Objective: This study evaluates the effects of resveratrol and caffeic acid on viability, proliferation, and apoptosis in ER⁺ MCF-7 breast cancer cells, with additional analysis of PTEN/AKT1-related transcriptional changes. Methods: MCF-7 cells were exposed to resveratrol at concentrations ranging from 5 to 50 µM and to caffeic acid at concentrations of 10 to 50 µM for incubation periods of 24, 48, and 72 h. Cell viability was assessed using the MTT assay. The expression levels of apoptosis-related genes (BAX, BCL-2, and CASP3), the proliferation marker CCND1, the estrogen receptor gene ESR1, and signaling pathway-related genes (PTEN and AKT1) were analyzed by quantitative real-time PCR. The BAX/BCL-2 ratio was calculated as an indicator of mitochondrial apoptotic balance. Results: Resveratrol treatment resulted in a significant, dose- and time-dependent reduction in MCF-7 cell viability compared with the control group (p0.05). At higher concentrations, resveratrol significantly upregulated the pro-apoptotic genes BAX and CASP3, while concurrently reducing BCL-2 expression, resulting in a marked increase in the BAX/BCL-2 ratio. In contrast, caffeic acid induced similar but less pronounced changes. Resveratrol significantly downregulated CCND1 and ESR1 expression at early time points and increased PTEN expression while reducing AKT1 expression after 48 hours, suggesting transcriptional regulation of the PTEN/AKT1 signaling pathway. Conclusion: These findings demonstrate that resveratrol exerts stronger anti-proliferative and pro-apoptotic effects than caffeic acid in ER⁺ MCF-7 breast cancer cells. The biological effects of resveratrol appear to be associated with the regulation of mitochondrial apoptosis and the PTEN/AKT1 signaling axis, supporting its potential role as a complementary therapeutic candidate in ER-positive breast cancer.

Özet

Amaç: Bu çalışmada, resveratrol ve kafeik asidin östrojen reseptörü pozitif (ER⁺) MCF-7 meme kanseri hücrelerinde hücre canlılığı, proliferasyon ve apoptoz üzerindeki etkileri değerlendirilmiş; ayrıca PTEN/AKT1 yolaklarıyla ilişkili transkripsiyonel değişiklikler mekanistik açıdan incelenmiştir. Yöntem: MCF-7 hücreleri, 5–50 µM konsantrasyon aralığında resveratrol ve 10–50 µM konsantrasyon aralığında kafeik asit ile 24, 48 ve 72 saat süreyle inkübe edilmiştir. Hücre canlılığı MTT yöntemi ile değerlendirilmiştir. Apoptozla ilişkili genler (BAX, BCL-2 ve CASP3), proliferasyon belirteci CCND1, östrojen reseptör geni ESR1 ve sinyal yolaklarıyla ilişkili genler (PTEN ve AKT1) kantitatif gerçek zamanlı PCR yöntemi kullanılarak analiz edilmiştir. Mitokondriyal apoptotik dengeyi yansıtmak amacıyla BAX/BCL-2 oranı hesaplanmıştır. Bulgular: Resveratrol uygulaması, kontrol grubuna kıyasla MCF-7 hücre canlılığında doza ve zamana bağlı anlamlı bir azalmaya yol açmıştır (p<0,05). Yüksek konsantrasyonlarda resveratrol, pro-apoptotik genler olan BAX ve CASP3 ekspresyonunu anlamlı şekilde artırırken, anti-apoptotik BCL-2 ekspresyonunu azaltmış ve buna bağlı olarak BAX/BCL-2 oranında belirgin bir artış oluşturmuştur. Buna karşılık, kafeik asit benzer yönde ancak daha sınırlı değişiklikler meydana getirmiştir. Resveratrol, erken zaman noktalarında CCND1 ve ESR1 ekspresyonunu anlamlı şekilde baskılamış; 48 saat sonunda ise PTEN ekspresyonunu artırırken AKT1 ekspresyonunu azaltmıştır. Bu bulgular, PTEN/AKT1 yolaklarıyla ilişkili transkripsiyonel düzenlemelere işaret etmektedir. Sonuç: Bu çalışmanın bulguları, resveratrolün ER⁺ MCF-7 meme kanseri hücrelerinde kafeik aside kıyasla daha güçlü anti-proliferatif ve pro-apoptotik etkilere sahip olduğunu göstermektedir. Resveratrolün biyolojik etkilerinin, mitokondriyal apoptozun düzenlenmesi ve PTEN/AKT1 sinyal yolaklarıyla ilişkili mekanizmalar aracılığıyla ortaya çıktığı düşünülmektedir. Bu sonuçlar, resveratrolün ER-pozitif meme kanserinde tamamlayıcı bir terapötik aday olabileceğini desteklemektedir.

🔖

Cite This Article

Korkmaz, O. (2026). COMPARATIVE EFFECTS OF RESVERATROL AND CAFFEIC ACID ON CELL VIABILITY, APOPTOSIS, AND PTEN/AKT1 SIGNALING IN MCF-7 BREAST CANCER CELLS. Acta Medica Nicomedia, Cilt: 9, 1–8. https://doi.org/10.53446/actamednicomedia.1882330

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (41)

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
  2. Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569. doi:10.3390/cancers14102569
  3. Kim N, Lukong KE. Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Rev. 2025;19:1564642. doi:10.3389/or.2025.1564642
  4. Miziak P, Baran M, Błaszczak E, et al. Estrogen receptor signaling in breast cancer. Cancers (Basel). 2023;15(19):4689. doi:10.3390/cancers15194689
  5. Zhang HP, Jiang RY, Zhu JY, et al. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539-551. doi: 10.1007/s12282-024-01567-5
  6. Mukherjee R, Vanaja KG, Boyer JA, et al. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol Cell. 2021;81(4):708-723.e5. doi:10.1016/j.molcel.2020.12.035
  7. Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget. 2017;8(19):32043-32054. doi:10.18632/oncotarget.16670
  8. Costa C, Wang Y, Ly A, et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer Discov. 2020;10(1):72-85. doi:10.1158/2159-8290.CD-18-0830
  9. Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal. 2019;17(1):154. doi:10.1186/s12964-019-0450-3
  10. Mustafa M, Ahmad R, Tantry IQ, et al. Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838. doi:10.3390/cells13221838
  11. Li Y, Li H, Quan J, et al. A risk model based on signature genes predicts prognosis and associates with tumor immunity and drug sensitivity in breast cancer. Cancer Biomark. 2025;42(7):18758592251357078. doi:10.1177/18758592251357078
  12. Li S, Yu X, Xu Y. Breast cancer gene expression signatures: development and clinical significance—a narrative review. Transl Breast Cancer Res. 2022;4:7. doi: 10.21037/tbcr-22-39
  13. Ren ZQ, Zheng SY, Sun Z, et al. Resveratrol: molecular mechanisms, health benefits, and potential adverse effects. MedComm (2020). 2025;6(6):e70252. doi:10.1002/mco2.70252
  14. Hedayati N, Safari MH, Milasi YE, et al. Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Disc Oncol. 2025;16(1):669. doi:10.1186/s13045-025-02090-z
  15. Behroozaghdam M, Dehghani M, Zabolian A, et al. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci. 2022;79(11):539. doi:10.1007/s00018-022-04511-x
  16. Gao Y, Wang YY, Wang BD, et al. Mechanism of action of Resveratrol affecting the biological function of breast cancer through the glycolytic pathway. World J Oncol. 2025;16(4):375-387. doi:10.14740/wjon1856
  17. Shi Y, Yang S, Troup S, et al. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep. 2011;25(6):1713-1719. doi:10.3892/or.2011.1237
  18. Yang H, Wang Y, Wang Y, et al. Advances of Resveratrol co-delivery biomaterials-based systems in anti-tumor therapy: a review. J Mater Sci Mater Med. 2025;36(1):112. doi:10.1007/s10856-025-06965-5
  19. Lee YJ, Kim KD, Choi MH, et al. Apoptosis, cell growth, and glycogen synthase kinase 3β phosphorylation in caffeic acid-treated human malignant melanoma cells. Biomedicines. 2025;13(10):2389. doi:10.3390/biomedicines13102389
  20. Bakrim S, El Omari N, El Hachlafi N, et al. Dietary phenolic compounds as anticancer natural drugs: recent update on molecular mechanisms and clinical trials. Foods (Basel). 2022;11(21):3323. doi:10.3390/foods11213323
  21. Rosendahl AH, Perks CM, Zeng L, et al. Caffeine and caffeic acid inhibit growth and modify estrogen receptor and insulin-like growth factor I receptor levels in human breast cancer. Clin Cancer Res. 2015;21(8):1877-1887. doi:10.1158/1078-0432.CCR-14-1748
  22. Hu C, Liu Y, Teng M, et al. Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling. Cell Biol Toxicol. 2019;35(5):445-456. doi:10.1007/s10565-019-09470-z
  23. Li Y, Liu J, Liu X, et al. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl Biochem Biotechnol. 2006;135(3):181-192. doi:10.1385/ABAB:135:3:181
  24. Schmidt B, Ferreira C, Alves Passos CL, et al. Resveratrol, Curcumin and Piperine Alter Human Glyoxalase 1 in MCF-7 Breast Cancer Cells. Int J Mol Sci. 2020;21(15):5244. doi:10.3390/ijms21155244
  25. Kabała-Dzik A, Rzepecka-Stojko A, Kubina R, et al. Caffeic Acid Versus Caffeic Acid Phenethyl Ester in the Treatment of Breast Cancer MCF-7 Cells: Migration Rate Inhibition. Integr Cancer Ther. 2018;17(4):1247-1259. doi:10.1177/1534735418780179
  26. Mahomoodally MF, Kowlessur E, Venugopala KN, et al. In vitro mechanistic insights into traditionally consumed food plants for breast cancer management. J Future Foods. 2025; Journal Pre-proof. doi:10.1016/j.jfutfo.2025.09.002
  27. Alkharashi NA. Efficacy of resveratrol against breast cancer and hepatocellular carcinoma cell lines. Saudi Med J. 2023;44(3):246-252. doi:10.15537/smj.2023.44.3.20220903
  28. Singh N, Nigam M, Ranjan V, et al. Caspase-mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. J Pharmacol Sci. 2009;109(4):473-485. doi:10.1254/jphs.08266FP
  29. Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep. 2004;11(2):441-446. doi:10.3892/or.11.2.441
  30. Putri GFT. Bax/Bcl-2 ratio as the golden marker of apoptosis: molecular mechanisms and regulatory pathways. Int J Cell Biomed Sci. 2025;4(10):309-317.
  31. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21(1):92-101. doi:10.1016/j.devcel.2011.06.017
  32. Alkhalaf M, El-Mowafy A, Renno W, et al. Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway. Arch Med Res. 2008;39(2):162-168. doi:10.1016/j.arcmed.2007.09.003
  33. Pozo-Guisado E, Merino JM, Mulero-Navarro S, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer. 2005;115(1):74-84. doi:10.1002/ijc.20856
  34. Filomeni G, Graziani I, Rotilio G, et al. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr. 2007;2(3):295-305. doi:10.1007/s12263-007-0051-4
  35. Ahlin C, Lundgren C, Embretsén-Varro E, et al. High expression of cyclin D1 is associated with high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat. 2017;164(3):667-678. doi:10.1007/s10549-017-4273-y
  36. Montalesi E, Cracco P, Acconcia F, et al. Resveratrol analogs and prodrugs differently affect the survival of breast cancer cells impairing estrogen/estrogen receptor α/neuroglobin pathway. Int J Mol Sci. 2023;24(3):2148. doi:10.3390/ijms24032148
  37. Chakraborty S, Levenson AS, Biswas PK. Structural insights into resveratrol’s antagonist and partial agonist actions on estrogen receptor alpha. BMC Struct Biol. 2013;13:27. doi:10.1186/1472-6807-13-27
  38. Kobylka P, Kucinska M, Kujawski J, et al. Resveratrol analogues as selective estrogen signaling pathway modulators: structure–activity relationship. Molecules. 2022;27(20):6973. doi:10.3390/molecules272068973
  39. Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol. 2020;50(5):439-462. doi:10.1080/10408444.2020.1740094
  40. Wang T, Heng YJ, Baker GM, et al. Loss of PTEN expression, PIK3CA mutations, and breast cancer survival in the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev. 2022;31(10):1926-1934. doi:10.1158/1055-9965.EPI-22-0418
  41. Ooms LM, Ferguson DT, Rodgers SJ, et al. Non-redundant roles of the phosphoinositide phosphatases PTEN and PIPP in PI3K/AKT signaling in breast cancer. Commun Biol. 2026;9:96. doi:10.1038/s42003-025-07970-0